Peter Hammerl

Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial

Jürgen Behr, Antje Prasse, Michael Kreuter et al. · The Lancet Respiratory Medicine · 2021 · 490 citations · Full text

Antifibrotic Therapy, Advanced Lung Disease, Idiopathic Pulmonary Fibrosis +6

Phenotypic characterization of alveolar monocyte recruitment in acute respiratory distress syndrome

Simone Rosseau, Peter Hammerl, Ulrich A. Maus et al. · American Journal of Physiology-Lung Cellular and Molecular Physiology · 2000 · 185 citations

Characterization of the cell death modes and the associated changes in cellular energy supply in response to AlPcS4-PDT

Kristjan Plaetzer, Tobias Kiesslich, Barbara Krammer et al. · Photochemical & Photobiological Sciences · 2002 · 97 citations

Signal Transduction, Cellular Energy Supply, Apoptosis +7

Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study

Toby M. Maher, Susanne Stowasser, Yasuhiko Nishioka et al. · The Lancet Respiratory Medicine · 2019 · 96 citations · Full text

Fibrosis, Extracellular Matrix Turnover, Inflammatory Lung Disease +7

Pulmonary hypertension due to chronic lung disease: Updated Recommendations of the Cologne Consensus Conference 2011

Marius M. Hoeper, Stefan Andreas, Andreas Bastian et al. · International Journal of Cardiology · 2011 · 79 citations

Hypertension, Pulmonary Arterial Hypertension, Health Policy +11